Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach
Basic & Clinical Pharmacology & Toxicology · 2026-05 · 138 (5)
DOI: 10.1111/bcpt.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 31.03.2026. Verfasst von Tianyi Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Triterpenes, Antineoplastic Agents. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Multiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS levels to toxic levels, thereby inducing apoptosis. Our previous study has demonstrated that pyridoxine‐5′‐phosphate oxidase (PNPO) is the specific target of celastrol. In this study, we discovered that PNPO, a key enzyme involved in vitamin B6 coenzyme metabolism, is highly expressed in various cancers, including MM. Increased PNPO levels correlated with MM disease progression, promoting cell proliferation and inducing osteoclast differentiation via exosomes. Concurrently, through a structure‐based virtual screening workflow targeting critical PNPO residues (R95 and K117), we identified Hetrombopag as a potential PNPO inhibitor. Hetrombopag simultaneously inhibited MM cell proliferation and osteoclast differentiation. Preliminary data from clinical trials also supported the idea that hetrombopag treatment can prolong survival in MM patients. Our research highlights the significant role of PNPO in MM progression and suggests hetrombopag as a promising therapeutic option for MM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- School of Elderly Care Services and Management, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Hematology and Oncology, Jing'an District Zhabei Central Hospital, Shanghai, China.
ORCID-Profile: Chunyan Gu
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Yu, T., Wang, C., Xie, J., Wei, Y., Cui, H., Zhang, H., Zhou, F., Deng, Z., Yang, Y., & Gu, C. (2026). Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach. Basic & Clinical Pharmacology & Toxicology, 138(5). https://doi.org/10.1111/bcpt.70227
Vancouver
Yu T, Wang C, Xie J, Wei Y, Cui H, Zhang H, et al. Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach. Basic & Clinical Pharmacology & Toxicology. 2026;138(5). doi:10.1111/bcpt.70227
BibTeX
@article{Yu2026,
author = {Yu, Tianyi and Wang, Cheng and Xie, Jingru and Wei, Yongxin and Cui, Hongwei and Zhang, Huaxia and Zhou, Fan and Deng, Zhendong and Yang, Ye and Gu, Chunyan},
title = {Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {138},
number = {5},
doi = {10.1111/bcpt.70227}
}
EUVIMED